Centessa Pharmaceuticals (NASDAQ:CNTA) reported quarterly losses of $(0.57) per share. This is a 26.67 percent decrease over losses of $(0.45) per share from the same period last year.
Adicet Bio Sets 2024 Goals: Advancing Allogeneic Gamma Delta T Cell Therapies in Oncology and Autoimmune
Adicet Bio, Inc. (NASDAQ:ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and autoimmune diseases, today provided corporate updates and